Dr. Jesse Keller is an Oncologist at the St. Louis VA and serves as PI on the newly approved project 'A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA'

Dr. Keller previously served as Co-Investigator on several completed Clinical Trials such as CANOPY and Talapro-2

Dr. Keller holds a DOD Prime award for his project 'A Novel Risk Prediction Model for Checkpoint Inhibitor–Related Autoimmune Toxicities' which is in the data analysis stages.